Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| LEXICON PHARMACEUTICALS, INC.LXRX · Entity 4970 | Director · 10% owner | August 05, 2022 | August 09, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
LEXICON PHARMACEUTICALS, INC.
Report date August 05, 2022 · Filed August 09, 2022
Jointly reported with Invus US Partners LLC, DEBBANE RAYMOND
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee Footnotes | 5,451,204 |
Reported balance
After 2022-08-05 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2022-08-05 · Purchase · Acquired 147,390 · Balance 5,451,204 F1: Pursuant to a purchase agreement dated July 27, 2022, between Invus US Partners LLC and the Issuer, on August 5, 2022, Invus US Partners LLC purchased an additional 147,390 shares of common stock, $0.001 par value per share (the "Issuer Common Stock"), following the full exercise by the underwriters of a concurrent public offering of their option to purchase additional shares of Issuer Common Stock. F2: These securities are directly held by Invus US Partners LLC F4: Ulys, L.L.C. is the general partner of Invus US Partners LLC, and Mr. Raymond Debbane is the sole member of Ulys, L.L.C. F5: Each of the Reporting Persons (other than to the extent it directly holds securities reported herein) disclaims beneficial ownership of the securities held by the other Reporting Persons, except to the extent of such Reporting Person's pecuniary interest therein, and, pursuant to Rule 16a-1(a)(4) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), each of the Reporting Persons (other than to the extent it directly holds securities reported herein) states that the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 of the Exchange Act or for any other purpose. |
| Common StockSEC Table I · non-derivative | Direct | 331,545 |
Reported balance
Holding disclosure · report date 2022-08-05 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 331,545 F3: These securities are directly held by Mr. Raymond Debbane. F4: Ulys, L.L.C. is the general partner of Invus US Partners LLC, and Mr. Raymond Debbane is the sole member of Ulys, L.L.C. F5: Each of the Reporting Persons (other than to the extent it directly holds securities reported herein) disclaims beneficial ownership of the securities held by the other Reporting Persons, except to the extent of such Reporting Person's pecuniary interest therein, and, pursuant to Rule 16a-1(a)(4) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), each of the Reporting Persons (other than to the extent it directly holds securities reported herein) states that the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 of the Exchange Act or for any other purpose. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to a purchase agreement dated July 27, 2022, between Invus US Partners LLC and the Issuer, on August 5, 2022, Invus US Partners LLC purchased an additional 147,390 shares of common stock, $0.001 par value per share (the "Issuer Common Stock"), following the full exercise by the underwriters of a concurrent public offering of their option to purchase additional shares of Issuer Common Stock.
F2: These securities are directly held by Invus US Partners LLC
F3: These securities are directly held by Mr. Raymond Debbane.
F4: Ulys, L.L.C. is the general partner of Invus US Partners LLC, and Mr. Raymond Debbane is the sole member of Ulys, L.L.C.
F5: Each of the Reporting Persons (other than to the extent it directly holds securities reported herein) disclaims beneficial ownership of the securities held by the other Reporting Persons, except to the extent of such Reporting Person's pecuniary interest therein, and, pursuant to Rule 16a-1(a)(4) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), each of the Reporting Persons (other than to the extent it directly holds securities reported herein) states that the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 of the Exchange Act or for any other purpose.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 05, 2022 Filed Aug 9, 2022 20:48 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | PurchaseCommon Stock | 147,390 | $2.50 | $368,475.00 |
DisclosureSEC source: 0000899243-22-028113 · doc4.xml · nonDerivative · entry 1 Invus US Partners LLC · CIK 0001839806 · Director · 10% owner Ulys, L.L.C. · CIK 0001340098 · Director · 10% owner DEBBANE RAYMOND · CIK 0001053890 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 5,451,204 F1 · kind: Pursuant to a purchase agreement dated July 27, 2022, between Invus US Partners LLC and the Issuer, on August 5, 2022, Invus US Partners LLC purchased an additional 147,390 shares of common stock, $0.001 par value per share (the "Issuer Common Stock"), following the full exercise by the underwriters of a concurrent public offering of their option to purchase additional shares of Issuer Common Stock. F2 · ownership.nature: These securities are directly held by Invus US Partners LLC F4 · ownership.nature: Ulys, L.L.C. is the general partner of Invus US Partners LLC, and Mr. Raymond Debbane is the sole member of Ulys, L.L.C. F5 · ownership.nature: Each of the Reporting Persons (other than to the extent it directly holds securities reported herein) disclaims beneficial ownership of the securities held by the other Reporting Persons, except to the extent of such Reporting Person's pecuniary interest therein, and, pursuant to Rule 16a-1(a)(4) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), each of the Reporting Persons (other than to the extent it directly holds securities reported herein) states that the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 of the Exchange Act or for any other purpose. Read SEC document |
| August 01, 2022 Filed Aug 1, 2022 20:15 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | PurchaseCommon Stock | 982,600 | $2.50 | $2,456,500.00 |
DisclosureSEC source: 0000899243-22-027157 · doc4.xml · nonDerivative · entry 1 Invus US Partners LLC · CIK 0001839806 · Director · 10% owner Ulys, L.L.C. · CIK 0001340098 · Director · 10% owner DEBBANE RAYMOND · CIK 0001053890 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 5,303,814 F1 · kind: On July 27, 2022, Invus US Partners LLC entered into a purchase agreement with the Issuer pursuant to which Invus US Partners LLC agreed to purchase 982,600 shares of common stock, $0.001 par value per share (the "Issuer Common Stock") of the Issuer at a price of $2.50 per share. The purchase closed on August 1, 2022. F2 · ownership.nature: These securities are directly held by Invus US Partners LLC F4 · ownership.nature: Ulys, L.L.C. is the general partner of Invus US Partners LLC, and Mr. Raymond Debbane is the sole member of Ulys, L.L.C. F5 · ownership.nature: Each of the Reporting Persons (other than to the extent it directly holds securities reported herein) disclaims beneficial ownership of the securities held by the other Reporting Persons, except to the extent of such Reporting Person's pecuniary interest therein, and, pursuant to Rule 16a-1(a)(4) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), each of the Reporting Persons (other than to the extent it directly holds securities reported herein) states that the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 of the Exchange Act or for any other purpose. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.